Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 5404131, 5 pages
https://doi.org/10.1155/2017/5404131
Case Report

Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia

1Baylor St. Luke’s Medical Center, Houston, TX 77030, USA
2Baylor College of Medicine, Section of Hematology and Oncology, 1 Baylor Plaza, Houston, TX 77030, USA
3Department of Pathology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA
4The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA

Correspondence should be addressed to Gustavo Rivero; ude.mcb@orevirag

Received 30 November 2016; Accepted 24 January 2017; Published 21 February 2017

Academic Editor: Akimichi Ohsaka

Copyright © 2017 Aristides Armas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. Arber, A. Orazi, R. Hasserjian et al., “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia,” Blood, vol. 127, no. 20, pp. 2391–2405, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. D. G. Roth, C. M. Richman, and J. D. Rowley, “Chronic myelodysplastic syndrome (preleukemia) with the Philadelphia chromosome,” Blood, vol. 56, no. 2, pp. 262–264, 1980. View at Google Scholar · View at Scopus
  3. A. Berrebi, R. Bruck, M. Shtalrid, and J. Chemke, “Philadelphia chromosome in idiopathic acquired sideroblastic anemia,” Acta Haematologica, vol. 72, no. 5, pp. 343–345, 1984. View at Google Scholar · View at Scopus
  4. Y.-K. Keung, M. Beaty, B. L. Powell, I. Molnar, D. Buss, and M. Pettenati, “Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia—retrospective study and review of literature,” Leukemia Research, vol. 28, no. 6, pp. 579–586, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Dutta, P. Kumari, N. Ks et al., “Philadelphia chromosome-positive myelodysplastic syndrome: is it a distinct entity?” Acta Haematologica, vol. 129, no. 4, pp. 215–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Ohyashiki, K. Ohyashiki, H. Fujieda et al., “Myelodysplastic syndrome with Philadelphia-like chromosome without bcr rearrangement,” Cancer Genetics and Cytogenetics, vol. 35, no. 2, pp. 151–158, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. M. W. Drummond, C. J. Lush, M. A. Vickers, F. M. Reid, J. Kaeda, and T. L. Holyoake, “Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome,” Leukemia, vol. 17, no. 2, pp. 463–465, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. F. Lesesve, X. Troussard, C. Bastard et al., “p190(bcr/abl) rearrangement in myelodysplastic syndromes: two reports and review of the literature,” British Journal of Haematology, vol. 95, no. 2, pp. 372–375, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Garcia-Manero, “Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management,” American Journal of Hematology, vol. 86, no. 6, pp. 490–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Kantarjian, F. Giles, A. List et al., “The incidence and impact of thrombocytopenia in myelodysplastic syndromes,” Cancer, vol. 109, no. 9, pp. 1705–1714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Neukirchen, S. Blum, A. Kuendgen et al., “Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes,” European Journal of Haematology, vol. 83, no. 5, pp. 477–482, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Kornblau, D. McCue, N. Singh, W. Chen, Z. Estrov, and K. R. Coombes, “Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia,” Blood, vol. 116, no. 20, pp. 4251–4261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Ozanne, A. R. Prescott, and K. Clark, “The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases,” Biochemical Journal, vol. 465, pp. 271–279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Toubiana, A.-L. Rossi, N. Belaidouni et al., “Src-family-tyrosine kinase Lyn is critical for TLR2-mediated NF-κ activation through the PI 3-kinase signaling pathway,” Innate Immunity, vol. 21, no. 7, pp. 685–697, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wei, S. Dimicoli, C. Bueso-Ramos et al., “Toll-like receptor alterations in myelodysplastic syndrome,” Leukemia, vol. 27, no. 9, pp. 1832–1840, 2013. View at Publisher · View at Google Scholar · View at Scopus